Enzolytics, Inc. (OTCMKTS:ENZC) Sees Significant Drop in Short Interest

Enzolytics, Inc. (OTCMKTS:ENZC) was the recipient of a large decline in short interest during the month of May. As of May 29th, there was short interest totaling 209 shares, a decline of 78.5% from the May 14th total of 972 shares. Based on an average daily volume of 10,580,690 shares, the days-to-cover ratio is presently 0.0 days.

Enzolytics Trading Down 16.7%

Shares of ENZC opened at $0.00 on Wednesday. Enzolytics has a 52-week low of $0.00 and a 52-week high of $0.00.

Enzolytics Company Profile

Enzolytics, Inc is a clinical-stage biotechnology company focused on advancing immunotherapeutic treatments for infectious diseases. Its core platform employs proprietary peptide and monoclonal antibody technologies designed to target and neutralize viral pathogens. The company’s lead candidate, Investigator Therapeutic Vaccine-1 (ITV-1), is a 72-amino-acid peptide engineered to bind multiple HIV-1 strains and support immune response in affected individuals.

In addition to its HIV program, Enzolytics has leveraged its antibody discovery engine to develop broadly neutralizing monoclonal antibodies against coronaviruses, including SARS-CoV-2.